DNDi response to the Report of the United Nations Secretary-General’s High-Level Panel on Access to Medicines

[14 September, 2016]
The Drugs for Neglected Diseases initiative (DNDi) today welcomes the release of the report of the United Nations Secretary General’s High-Level Panel on Access to Medicines. The Panel has clearly confirmed the policy misalignment between intellectual property and trade rules, international human rights obligations, and public health objectives. It has underlined many immediate access challenges and steps that must be taken to overcome them, and highlighted that existing funding and incentive mechanisms are not adequate to stimulate innovation to address global public health needs.

L-intégration [3 December, 2015]
“Promotion des Essais cliniques: Mutualiser les ressources, pour être plus efficace et gagner du temps – dixit Dr Nathalie Strub Wourgaft” – “Promotion of Clinical Trials: Pooling resources to be more efficient and save time – Dr Nathalie Strub Wourgaft”
Click here to read the article

New report reviews the successful development of the antimalarial ASAQ

DNDi has produced a new report on ‘Pioneering ways of working through innovative partnerships – 2002-2015 – The successful development of a fixed dose combination of artesunate plus amodiaquine antimalarial’. This document reviews the development of DNDi’s first-delivered treatment, ASAQ FDC, and forms part of a broader reflection on DNDi’s business model and its lessons learned over a decade after its creation in 2003.

DNDi joins call for amendments to the FDA Priority Review Voucher programme

The Drugs for Neglected Diseases initiative (DNDi) has joined Médecins Sans Frontières/Doctors Without Borders (MSF), the Global Alliance for TB Drug Development (TB Alliance), and other not-for-profit public health organizations in calling for amendments to the Food and Drug Administration (FDA) Priority Review Voucher (PRV) programme for neglected diseases.

L’AFD et DNDi signent un accord de partenariat pour lutter contre la leishmaniose en Afrique de l’Est

[Paris, France et Genève, Switzerland – 8 October 2015]
L’Agence Française de Développement (AFD) et l’initiative Médicaments contre les Maladies Négligées (Drugs for Neglected Diseases initiative – DNDi) ont signé aujourd’hui un accord de partenariat de 2 millions d’euros jusqu’à fin 2018 pour lutter contre la leishmaniose en Afrique de l’Est (Soudan, Ethiopie, Kenya et Ouganda) et développer un nouveau traitement oral, efficace et sûr.

DNDi awarded USD 2.34 million from new pooled fund mechanism at WHO-TDR in support of global leishmaniasis R&D demonstration project

[Geneva, Switzerland – 6 October 2015]
The Drugs for Neglected Diseases initiative (DNDi) has been awarded USD 2.34 million from a new pooled fund for health research and development (R&D) set up by Member States of the World Health Organization (WHO) and hosted by the Special Programme for Research and Training in Tropical Diseases (WHO-TDR), for a large-scale R&D project for the parasitic disease leishmaniasis.
[Español] [Português]

Drugs for Neglected Diseases initiative unveils new plan for neglected patients

[Basel, Switzerland – 7 September 2015]
Aims to Deliver 16-18 Treatments for Up to 10 Diseases with EUR 650 Million
After having built the world’s largest drug development pipeline for the most neglected diseases, the Drugs for Neglected Diseases initiative (DNDi) has unveiled plans for a more flexible, dynamic portfolio approach, integrating various operating models to better respond to the needs of patients, notably in low- and middle-income countries. The plan also paves the way for new diseases to be taken up in DNDi’s portfolio.
[English] [Español] [Français] [Português]

Le nouveau plan d’affaires de DNDi

[Bâle, Suisse – 7 septembre 2015]
Objectif: 16 à 18 traitements d’ici à 2023 pour 10 maladies avec un budget total de 650 ME 
Après avoir développé le plus important portefeuille de recherche et développement (R&D) de médicaments contre les maladies les plus négligées, l’Initiative médicaments contre les maladies négligées (DNDi) a élaboré son nouveau plan d’affaires avec l’adoption d’une approche plus souple et dynamique, intégrant dans son portefeuille de nouvelles maladies ainsi que différents modèles opérationnels afin de mieux répondre aux besoins des patients, notamment ceux des pays à faible revenu et à revenu moyen.
[English] [Español] [Français] [Português]